Heron Therapeutics (HRTX) Hits New 1-Year High at $18.58

Heron Therapeutics Inc (NASDAQ:HRTX) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $18.58 and last traded at $17.65, with a volume of 973000 shares traded. The stock had previously closed at $17.65.

Several brokerages have recently issued reports on HRTX. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Oppenheimer set a $27.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 14th. Mizuho initiated coverage on Heron Therapeutics in a report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 target price on the stock. Northland Securities initiated coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Noble Financial reissued a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Heron Therapeutics has an average rating of “Buy” and an average price target of $28.73.

The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1,132.76, a P/E ratio of -4.84 and a beta of 2.13.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The company had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. equities research analysts expect that Heron Therapeutics Inc will post -3.41 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc grew its stake in shares of Heron Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 12,024 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $206,000. Jane Street Group LLC bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $223,000. Finally, HighTower Advisors LLC grew its stake in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the last quarter. 98.78% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Heron Therapeutics (HRTX) Hits New 1-Year High at $18.58” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/24/heron-therapeutics-hrtx-hits-new-1-year-high-at-18-58.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit